Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: A quality improvement programme

Acta Psychiatrica Scandinavica

Volumn 118, Issue 1, 2008, Pages 26-33

  Barnes, T R E ^a   Paton, C ^a   Hancock, E ^b   Cavanagh, M R ^b   Taylor, D ^c   Lelliott, P ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ROYAL COLLEGE OF PSYCHIATRISTS   (United Kingdom)

^c SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antipsychotics; Metabolic syndrome; Screening

Indexed keywords

CLOZAPINE; LIPID; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD PRESSURE; DATA ANALYSIS; DIABETES MELLITUS; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL PATIENT; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; QUALITY CONTROL; SCREENING; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENCHMARKING; BODY WEIGHT; COMMUNITY MENTAL HEALTH SERVICES; COMMUNITY-INSTITUTIONAL RELATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENGLAND; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; LIFE STYLE; MALE; MASS SCREENING; MEDICAL AUDIT; METABOLIC SYNDROME X; MIDDLE AGED; MOOD DISORDERS; PHYSICAL EXAMINATION; PSYCHOTIC DISORDERS; QUALITY ASSURANCE, HEALTH CARE; QUALITY INDICATORS, HEALTH CARE; QUESTIONNAIRES; REFERENCE STANDARDS; REMINDER SYSTEMS; RETROSPECTIVE STUDIES;

EID: 45149120526     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2008.01203.x     Document Type: Article

References (39)

1. Barnes TRE, Kerwin R. Mortality and sudden death in schizophrenia. In : Camm J, ed. Cardiovascular risk associated with schizophrenia and its treatment. London : Galliard Healthcare Communications, 2003 : 7 23.
2. Osborn DPJ, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. Arch Gen Psychiatry 2007 64 : 242 249.
3. Mackin P, Bishop D, Watkinson H, Gallagher P, Ferrier N. Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psychiatry 2007 191 : 23 29.
4. Suvisaari JM, Saarni SI, Perala J et al. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psychiatry 2007 68 : 1045 1055.
5. Brown S, Birtwistle J, Roe L et al. The unhealthy lifestyles of people with schizophrenia. Psychol Med 1999 29 : 697 701.
6. van Nimwegen LJ, Storosum JG, Blumer RM et al. Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab 2008 93 : 572 577.
7. Saari K, Koponen H, Laitinen J et al. Hyperlipidaemia in persons using antipsychotic medication: a general population based birth cohort study. J Clin Psychiatry 2004 65 : 547 550.
8. Haddad PM. Antipsychotics and diabetes: review of -prospective data. Br J Psychiatry 2004 184 : S80 S86.
9. Taylor D, Young C, Esop R et al. Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. J Psychopharmacol 2005 19 : 182 186.
10. Grundy SM, Brewer HB, Cleeman JL et al. Definition of the metabolic syndrome. Circulation 2004 109 : 433 438.
11. Laaksonen DE, Niskanen L, Lakka H-M, Lakka TA, Uusitupa M. Epidemiology and treatment of the metabolic syndrome. Ann Med 2004 36 : 332 346.
12. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007 68 (suppl. 4 8 13.
13. Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003 64 : 575 579.
14. Goethe JW, Szarek BL, Caley CF, Woolley SB. Signs and symptoms associated with the metabolic syndrome in psychiatric inpatients receiving antipsychotics: a retrospective chart review. J Clin Psychiatry 2007 68 : 22 28.
15. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006 23 : 469 480.
16. Expert Panel on Detection and Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001 285 : 2486 2497.
17. National Institute for Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. 2002, Clinical Guideline 1, available at: http://www.nice.org. uk.
18. Barnes TRE, Paton C, Cavanagh M-R, Hancock E, Taylor DM on behalf of the UK Prescribing Observatory for Mental Health. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr Bull 2007 33 : 1397 1401.
19. Paton C, Esop R, Young C et al. Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand 2004 110 : 299 305.
20. Taylor D, Young C, Esop R et al. Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry 2004 85 : 152 156.
21. American Diabetes Association & American Psychiatric Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004 27 : 596 601.
22. Lambert TJR, Chapman LH on behalf of the Consensus Working Group (2004) Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 2004 181 : 544 548.
23. De Hert MA, van Winkel R, Van Eyck D et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006 83 : 87 93.
24. Rowlands P. The NICE schizophrenia guidelines: the challenge of implementation. Adv Psychiatr Treat 2004 10 : 403 412.
25. Drake RE, Torrey WC, McHugo GJ. Strategies for implementing evidence-based practices in routine mental health settings. Evid Based Ment Health 2003 6 : 6 7.
26. Jamtvedt G, Young JM, Kristoffersen DT et al. Audit and feedback: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2006 art. no.: CD000259 doi :.
27. Patrick V, Schleifer SJ, Nurenberg JR et al. An initiative to curtail the use of antipsychotic polypharmacy in a state psychiatric hospital. Psychiatr Serv 2006 57 : 21 23.
28. O'Brien MA, Freemantle N, Oxman AD et al. Continuing education meetings and workshops: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2001 art. no.: CD003030 doi :.
29. Grimshaw J, Eccles M, Tetroe J. Implementing clinical guidelines: current evidence and future implications. J Contin Educ Health Prof 2004 24 (suppl. 1 S31 S37.
30. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002 287 : 356 359.
31. Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004 49 : 753 760.
32. Hägg S, Lindblom Y, Mjörndal T, Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006 21 : 93 98.
33. Lamberti JS, Olson D, Crilly JF et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006 163 : 1273 1276.
34. Meyer JM, Davis VG, Goff DC et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res 2008 doi : [Epub ahead of print].
35. Tirupati S, Chua LE. Obesity and metabolic syndrome in a psychiatric rehabilitation service. Aust N Z J Psychiatry 2007 41 : 606 610.
36. Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007 89 : 91 100.
37. McEvoy JP, Meyer JM, Goff DC et al. Prevalence of the metabolic syndrome in patients with schizophrenia : Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES 111. Schizophr Res 2005 80 : 19 32.
38. Brown MJ. Hypertension and ethnic group. Br Med J 2006 332 : 833 836.
39. Diaz VA, Mainous AG III., Baker R, Carnemolla M, Majeed A. How does ethnicity affect the association between obesity and diabetes? Diabet Med 2007 24 : 1199 1204.